Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
376 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2014', provides an overview of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 Introduction 6 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Overview 7 Therapeutics Development 8 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Development by Companies 10 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Investigation by Universities/Institutes 17 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Products Glance 20 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Development by Companies 23 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Investigation by Universities/Institutes 30 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Companies Involved in Therapeutics Development 33 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics Assessment 107 Drug Profiles 122 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Recent Pipeline Updates 300 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Dormant Projects 347 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Discontinued Products 349 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Product Development Milestones 350 Appendix 360
List of Tables Number of Products under Development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, H2 2014 23 Number of Products under Development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Comparative Analysis, H2 2014 24 Number of Products under Development by Companies, H2 2014 26 Number of Products under Development by Companies, H2 2014 (Contd..1) 27 Number of Products under Development by Companies, H2 2014 (Contd..2) 28 Number of Products under Development by Companies, H2 2014 (Contd..3) 29 Number of Products under Development by Companies, H2 2014 (Contd..4) 30 Number of Products under Development by Companies, H2 2014 (Contd..5) 31 Number of Products under Investigation by Universities/Institutes, H2 2014 33 Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 34 Comparative Analysis by Late Stage Development, H2 2014 35 Comparative Analysis by Clinical Stage Development, H2 2014 36 Comparative Analysis by Early Stage Development, H2 2014 37 Products under Development by Companies, H2 2014 38 Products under Development by Companies, H2 2014 (Contd..1) 39 Products under Development by Companies, H2 2014 (Contd..2) 40 Products under Development by Companies, H2 2014 (Contd..3) 41 Products under Development by Companies, H2 2014 (Contd..4) 42 Products under Development by Companies, H2 2014 (Contd..5) 43 Products under Development by Companies, H2 2014 (Contd..6) 44 Products under Investigation by Universities/Institutes, H2 2014 45 Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 46 Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 47 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by AstraZeneca PLC, H2 2014 48 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by GlaxoSmithKline plc, H2 2014 49 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by AmpliPhi Biosciences Corporation, H2 2014 50 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Piramal Enterprises Limited, H2 2014 51 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Melinta Therapeutics, Inc, H2 2014 52 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Aphios Corporation, H2 2014 53 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014 54 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Ildong Pharmaceutical Co., Ltd., H2 2014 55 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by The Medicines Company, H2 2014 56 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Wockhardt Limited, H2 2014 57 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Paratek Pharmaceuticals, Inc., H2 2014 58 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Alchemia Limited, H2 2014 59 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Helix BioMedix, Inc., H2 2014 60 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Aptose Biosciences Inc., H2 2014 61 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by BioDiem Ltd, H2 2014 62 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by NovaBay Pharmaceuticals, Inc., H2 2014 63 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Oragenics, Inc., H2 2014 64 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Yungjin Pharm Ind. Co., Ltd., H2 2014 65 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Soligenix, Inc., H2 2014 66 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by MorphoSys AG, H2 2014 67 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Galapagos NV, H2 2014 68 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by CrystalGenomics, Inc., H2 2014 69 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by C3 Jian, Inc, H2 2014 70 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Debiopharm International S.A., H2 2014 71 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Aurigene Discovery Technologies Limited, H2 2014 72 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Bharat Biotech International Limited, H2 2014 73 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Immupharma Plc, H2 2014 74 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Evolva SA, H2 2014 75 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Quantum Pharmaceuticals, H2 2014 76 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Novabiotics Ltd, H2 2014 77 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by ConjuGon, Inc., H2 2014 78 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H2 2014 79 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Therametrics holding AG, H2 2014 80 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Destiny Pharma Ltd., H2 2014 81 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by NovaDigm Therapeutics, Inc., H2 2014 82 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Syntiron LLC, H2 2014 83 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Nabriva Therapeutics AG, H2 2014 84 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Microbiotix, Inc., H2 2014 85 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Enanta Pharmaceuticals, Inc., H2 2014 86 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Cempra, Inc., H2 2014 87 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Cellceutix Corporation, H2 2014 88 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2014 89 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Pepscan Presto BV, H2 2014 90 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2014 91 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Taejoon Pharm Co., Ltd., H2 2014 92 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Medisyn Technologies, Inc., H2 2014 93 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Phico Therapeutics Ltd., H2 2014 94 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by AIMM Therapeutics B.V., H2 2014 95 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Savara Inc., H2 2014 96 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Sorrento Therapeutics, Inc., H2 2014 97 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by TAXIS Pharmaceuticals, Inc., H2 2014 98 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Ensoltek Co., Ltd., H2 2014 99 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Motif BioSciences, Inc., H2 2014 100 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Revivicor, Inc., H2 2014 101 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Durata Therapeutics, Inc., H2 2014 102 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by XBiotech USA, Inc., H2 2014 103 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by PharmaIN Corporation, H2 2014 104 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Excelimmune, Inc., H2 2014 105 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by LegoChem Biosciences, Inc, H2 2014 106 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Techulon, Inc., H2 2014 107 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Procarta Biosystems Ltd, H2 2014 108 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by MGB Biopharma Limited, H2 2014 109 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Absynth Biologics Limited, H2 2014 110 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Sentinella Pharmaceuticals, Inc., H2 2014 111 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by DesignMedix, Inc., H2 2014 112 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Microbion Corporation, H2 2014 113 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by ContraFect Corporation, H2 2014 114 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by ImmuVen, Inc., H2 2014 115 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Novolytics Limited, H2 2014 116 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Sealife PHARMA GMBH, H2 2014 117 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by iNtRON Biotechnology Inc., H2 2014 118 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Pono Pharma, H2 2014 119 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Adenium Biotech ApS, H2 2014 120 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Dong-A Socio Group, H2 2014 121 Assessment by Monotherapy Products, H2 2014 122 Assessment by Combination Products, H2 2014 123 Number of Products by Stage and Target, H2 2014 126 Number of Products by Stage and Mechanism of Action, H2 2014 130 Number of Products by Stage and Route of Administration, H2 2014 133 Number of Products by Stage and Molecule Type, H2 2014 136 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics - Recent Pipeline Updates, H2 2014 315 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Dormant Projects, H2 2014 362 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Discontinued Products, H2 2014 364
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
